Apogee Therapeutics, Inc. · Brief

Next report

9 days

Nov 9 · before openest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

0 of 8≥ implied

Aug 12 '24±12.1%▲+9.78%×0.81

Nov 12 '24±7.7%▼−5.14%×0.67

Mar 3 '25±12.0%▼−0.16%×0.01

May 12 '25±13.0%▲+6.14%×0.47

Aug 11 '25±7.7%▼−2.09%×0.27

Q3 FY25±8.7%▲+3.77%×0.43

Q1 FY26±7.8%▲+1.89%×0.24

Q2 FY26±0.6%▼−0.14%×0.23

quarterimplied−15%0+15%realized×

Q2 FY26±0.6%▼−0.14%×0.23

Q1 FY26±7.8%▲+1.89%×0.24

Q3 FY25±8.7%▲+3.77%×0.43

Aug '25±7.7%▼−2.09%×0.27

May '25±13.0%▲+6.14%×0.47

Mar '25±12.0%▼−0.16%×0.01

2 older reports

Nov '24±7.7%▼−5.14%×0.67

Aug '24±12.1%▲+9.78%×0.81

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 9 report · est.

Bull2

291managers reporting a position in the latest quarterly filings13F · Jun 30 '26

8 of 8recent reports where the move came in under the options implied rangeEarnings history

Bear2

5tracked funds holding APGEN-PORT · Aug 31 '26

1.49%of State Street SPDR S&P Biotech ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

APGE report session

No linked exposure.

No changes.

privateThesis 0 · Decisions 0 · Observations 0

No thesis.